文献速递神经肌肉病

ω-3补充剂对1型糖尿病神经病变的影响:12个月初步试验

Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial.
PubMed 文献 · Neurology · 2017-05-17

主要结局角膜神经纤维长度从基线8.3 ± 2.9 mm/mm2增加29%至10.1 ± 3.7 mm/mm2(p = 0.002),神经传导和感觉功能无变化。结论认为12个月ω-3补充与角膜神经纤维长度增加相关。

要点

  • 1型糖尿病伴神经病变证据患者补充海豹油ω-3多不饱和脂肪酸12个月。
  • 角膜神经纤维长度从8.3 ± 2.9 mm/mm2增加29%至10.1 ± 3.7 mm/mm2(p = 0.002)。
  • 神经传导和感觉功能未见变化。

核心结论

  • 12个月ω-3补充与1型糖尿病患者角膜神经纤维长度增加相关。
  • 该研究提供IV级证据表明12个月海豹油ω-3补充可增加角膜神经纤维长度。

研究设计与样本

  • 干预为海豹油ω-3多不饱和脂肪酸10 mL·d-1,含750 mg二十碳五烯酸、560 mg二十二碳五烯酸和1,020 mg二十二碳六烯酸,持续1年。
  • 主要结局为12个月时经活体角膜共聚焦显微镜测量的角膜神经纤维长度变化,感觉和神经传导指标为次要结局。

主要发现

  • 基线时23例有临床糖尿病感觉运动多发性神经病变,17例无。
  • 基线角膜神经纤维长度为8.3 ± 2.9 mm/mm2,12个月补充后增加29%至10.1 ± 3.7 mm/mm2(p = 0.002)。
  • 神经传导或感觉功能无变化。

临床怎么用

  • 对于1型糖尿病伴糖尿病感觉运动多发性神经病变证据的患者,可考虑12个月海豹油ω-3多不饱和脂肪酸补充以改善角膜神经纤维长度。
  • 该干预对神经传导和感觉功能未见改善,临床决策需结合个体情况。

局限性

  • 单臂、开放标签设计,无对照组。
  • 证据等级为IV级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the hypothesis that 12 months of seal oil omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation will stop the known progression of diabetic sensorimotor polyneuropathy (DSP) in type 1 diabetes mellitus (T1DM). METHODS: Individuals with T1DM and evidence of DSP as determined by a Toronto Clinical Neuropathy Score ≥1 were recruited to participate in a single-arm, open-label trial of seal oil ω-3 PUFA supplementation (10 mL·d-1; 750 mg eicosapentaenoic acid, 560 mg docosapentaenoic acid, and 1,020 mg docosahexaenoic acid) for 1 year. The primary outcome was the 1-year change in corneal nerve fiber length (CNFL) measured by in vivo corneal confocal microscopy, with sensory and nerve conduction measures as secondary outcomes. RESULTS: Forty participants (53% female), aged 48 ± 14 years, body mass index 28.1 ± 5.8 with diabetes duration of 27 ± 18 years, were enrolled. At baseline, 23 participants had clinical DSP and 17 did not. Baseline CNFL was 8.3 ± 2.9 mm/mm2 and increased 29% to 10.1 ± 3.7 mm/mm2 (p = 0.002) after 12 months of supplementation. There was no change in nerve conduction or sensory function. CONCLUSIONS: Twelve months of ω-3 supplementation was associated with increase in CNFL in T1DM. CLINICALTRIALSGOVIDENTIFIER: NCT02034266. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with T1DM and evidence of DSP, 12 months of seal oil omega-3 supplementation increases CNFL.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lewis EJH, Perkins BA, Lovblom LE, et al. Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial. Neurology. 2017. PMID: 28515269. doi:10.1212/WNL.0000000000004033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。